European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults (Bristol-Myers Squibb Company)

(Source: Bristol-Myers Squibb Company) The European Commission approval is based upon Phase III clinical trial - Reyataz®(atazanavir) and cobicistat combination demonstrated virologic failure rates as low as 6% at 48 weeks and 8% at 144 weeks [HIV-1 RNA ≥50 copies/mL: 6% Reyataz/cobicistat arm and 4% Reyataz/ritonavir arm at 48 weeks; 8% Reyataz/cobicistat arm and 5% Reyataz/ritonavir arm at 144 weeks] Reyataz/cobicistat safety was demonstrated through 144 weeks in clinical trials Dateline: "Preventing resistance is a paramount consideration for management of HIV, and a critical success factor in suppressing the disease." PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb...